4579 Stock Overview
Engages in the research and development of pharmaceutical compounds worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
RaQualia Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥384.00 |
| 52 Week High | JP¥720.00 |
| 52 Week Low | JP¥362.00 |
| Beta | 0.67 |
| 1 Month Change | -14.86% |
| 3 Month Change | -27.68% |
| 1 Year Change | -44.19% |
| 3 Year Change | -67.29% |
| 5 Year Change | -70.80% |
| Change since IPO | -74.40% |
Recent News & Updates
Recent updates
Market Participants Recognise RaQualia Pharma Inc.'s (TSE:4579) Revenues Pushing Shares 27% Higher
Sep 04
With RaQualia Pharma Inc. (TSE:4579) It Looks Like You'll Get What You Pay For
Jul 17Companies Like RaQualia Pharma (TYO:4579) Can Afford To Invest In Growth
Apr 02The RaQualia Pharma (TYO:4579) Share Price Has Soared 410%, Delighting Many Shareholders
Feb 08
Companies Like RaQualia Pharma (TYO:4579) Can Afford To Invest In Growth
Dec 17Shareholder Returns
| 4579 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | 4.1% | 0.9% | 2.1% |
| 1Y | -44.2% | 11.8% | 15.6% |
Return vs Industry: 4579 underperformed the JP Pharmaceuticals industry which returned 12.8% over the past year.
Return vs Market: 4579 underperformed the JP Market which returned 16.3% over the past year.
Price Volatility
| 4579 volatility | |
|---|---|
| 4579 Average Weekly Movement | 4.3% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in JP Market | 7.2% |
| 10% least volatile stocks in JP Market | 1.8% |
Stable Share Price: 4579 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4579's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 87 | Hirobumi Takeuchi | www.raqualia.co.jp |
RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. Its human products portfolio includes tegoprazan for gastroesophageal reflux disease, which is in phase 3 clinical trial in the United States; and grapiprant for cancer, which is in phase I clinical trial in China and the United States, as well as grapiprant for pain management The company also provides veterinary products, such as grapiprant for osteoarthritis in dogs; ghrelin receptor agonist to treat cancer-related anorexia/cachexia syndrome, and constipation resulting from spinal cord injury; and ELURA, a drug for the management of weight loss in cats with chronic kidney disease. In addition, it provides TRPM8 blocker for the indication of chronic pain; motilin receptor agonist to treat gastrointestinal dysmotility, including gastroparesis, functional dyspepsia, and post-operative ileus; 5-HT4 partial agonist to treat gastroparesis, functional dyspepsia, and chronic constipation; 5-HT2B antagonist to treat irritable bowel syndrome with diarrhea; EP4 antagonist, a pain management drugs for dogs; serotonin 5-HT2A and dopamine D2 receptor blocker to treat schizophrenia; EP4 antagonist to treat cancer that is in phase I clinical trial; Cyclooxygenase-2 inhibitor, which is in phase I clinical trials for the indication of pain; CB2 agonist for pain; selective sodium channel blocker for pain and itch; P2X7 receptor antagonist, which is in Phase 2 clinical trials for the target indication of chronic pain.
RaQualia Pharma Inc. Fundamentals Summary
| 4579 fundamental statistics | |
|---|---|
| Market cap | JP¥8.31b |
| Earnings (TTM) | -JP¥545.92m |
| Revenue (TTM) | JP¥2.78b |
3.0x
P/S Ratio-15.2x
P/E RatioIs 4579 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4579 income statement (TTM) | |
|---|---|
| Revenue | JP¥2.78b |
| Cost of Revenue | JP¥452.48m |
| Gross Profit | JP¥2.32b |
| Other Expenses | JP¥2.87b |
| Earnings | -JP¥545.92m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 14, 2025
| Earnings per share (EPS) | -25.23 |
| Gross Margin | 83.70% |
| Net Profit Margin | -19.67% |
| Debt/Equity Ratio | 58.5% |
How did 4579 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 05:51 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
RaQualia Pharma Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Akitada Iwasa | Daiwa Securities Co. Ltd. |
| Kiyokazu Yamazaki | Ichiyoshi Research Institute Inc. |
| Shinya Tsuzuki | Mizuho Securities Co., Ltd. |